



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurgaon (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

February 13, 2017

The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block – G
Bandra-Kurla Complex, Bandra
Mumbai – 400 051

Dear Sir/Madam,

Sub: Unaudited Financial Results for the quarter ended on December 31, 2016

We would like to inform you that the Board of Directors at its meeting held on Monday, February 13, 2017 at 2:00 p.m. at its Corporate office at 24 & 25 Floor, One Horizon Centre, DLF Phase V, Golf Course Road, Gurgaon 122 002, have, inter alia, considered and taken on record the unaudited financial results for the quarter ended December 31, 2016. We are enclosing a copy of the Unaudited Financial Results for the quarter ended December 31, 2016 along with the "Limited Review" Certificate, issued by the Statutory Auditors for the review done by them, for your records.

This is further to inform you that the tenure of Mr. Subodh Bhargava as a Non-Executive Chairman of the Company has been extended further for a period of one year with effect from March 31, 2017 till March 31, 2018.

The above may please be taken as our intimation under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking You

Yours faithfully
For GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary
M. No. ACS-13405

CIN: L24231PB1958PLC002257
Registered Office
Patiala Road
Nabha (Punjab), India 147201

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabna - 147 201 (Punjab).
Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurgaon - 122 002, Haryana.
Tel. No. 01765-306400; Fax No. 01765-220642



CIN: L24231PB1958PLC002257
Email ID: investor.2.co@gsk.com
Website: www.gsk-ch.in

Statement of Standalone Unaudited Results for the Quarter ended December 31, 2016 (Rs. in Lakhs)					
PARTICULARS	3 Months Ended 31/12/2016	Preceding 3 Months Ended 30/09/2016	Corresponding 3 Months Ended 31/12/2015 in the previous year	Year to date figures for the previous year ended (9 Months) 31/12/2016	Year to date figures for the previous year ended (9 Months) 31/12/2015
(Refer Notes Below)	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED
1 Income from Operations					
(a) Net Sales / Income from Operations	9,21,64	11,35,60	10,55,57	30,59,86	32,25,78
(b) Other Operating Income	38,53	57,16	40,71	1,52,47	1,46,38
Total Income from operations	9,60,17	11,92,76	10,96,28	32,12,33	33,72,16
2 Expenses					
(a) Cost of materials consumed	2,57,62	3,04,44	3,46,43	8,51,03	9,21,76
(b) Purchase of stock-in-Trade	41,13	40,58	32,25	1,06,66	1,00,30
(c) Change of inventories of finished goods, work-in-progress and stock-in-trade	(21,64)	22,13	(74,73)	(37,18)	(24,24)
(d) Excise Duty	99,78	1,12,49	1,24,58	3,27,74	3,13,31
(e) Employee benefits expense	1,06,66	1,30,74	1,21,19	3,54,41	3,62,19
(f) Advertising & Promotion	92,42	1,27,19	1,25,04	3,41,15	3,88,79
(g) Depreciation and Amortisation expense	17,07	14,75	13,83	46,48	42,85
(h) Other Expenses	2,16,51	2,10,02	2,36,27	6,52,10	6,85,75
Total Expenses	8,09,55	9,62,34	9,24,86	26,42,39	27,90,71
3 Profit from operations before other income, finance costs and exceptional Items (1-2)	1,50,62	2,30,42	1,71,42	5,69,94	5,81,45
4 Other income	55,92	57,82	57,58	1,72,92	1,71,39
5 Profit before finance costs and exceptional Items (3+4)	2,06,54	2,88,24	2,29,00	7,42,86	7,52,84
6 Finance costs	63	64	66	1,91	2,02
7 Profit before exceptional items (5-6)	2,05,91	2,87,60	2,28,34	7,40,95	7,50,82
8 Exceptional items (Refer Note 6)	-	-	-	-	56,05
9 Profit / (Loss) before tax (7 +/- 8)	2,05,91	2,87,60	2,28,34	7,40,95	8,06,87
10 Tax expense	69,50	1,03,88	79,66	2,60,16	2,81,81
11 Net Profit / (Loss) for the period (9 +/- 10)	1,36,41	1,83,72	1,48,68	4,80,79	5,25,06
12 Other comprehensive income, net of income tax					
A Items that will not be reclassified to profit or loss	11,90	8,39	(17,25)	18,87	(20,10)
B Items that will be reclassified to profit or loss	-	-	-	-	-
Total other comprehensive income, net of income tax	11,90	8,39	(17,25)	18,87	(20,10)
13 Total comprehensive income for the period (11 +/- 12)	1,48,31	1,92,11	1,31,43	4,99,66	5,04,96
14 Paid Up equity share capital (Face Value of Equity Shares)	42,06 10	42,06 10	42,06 10	42,06 10	42,06 10
15 Earnings per share (of Rs 10/- each) (not annualised):					
(a) Basic and					
(b) Diluted	32.43	43.68	35.35	114.31	124.84
See accompanying note to the financial results					



Mamij Kumar

Notes to the financial results:

1. This statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 13, 2017. The statutory auditors have carried out limited review of the standalone results for the quarter ended December 31, 2016.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015.
3. The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
4. Basis management assessment, the Company has only one reportable segment which is Nutrition. Accordingly no separate disclosure of segment information have been made.
5. The statement does not include Ind AS compliant statement of results for the previous year ended March 31, 2016 as the same is not mandatory as per SEBI's circular dated July 5, 2016.
6. Exceptional item represents provision relating to previous years/ quarter no longer required and written back on account of receipt of a favourable order dated October 5, 2015 from tax authorities.
7. The reconciliation of net profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Description	Corresponding 3 months ended in the previous year (31/12/2015)	Corresponding 9 months ended previous year (31/12/2015)
	UNAUDITED	UNAUDITED
Net profit or loss as per Previous GAAP (Indian GAAP)	13,185	50,623
Add/(Less) : Adjustments		
Impact of finance lease including related impairment adjustments	(46)	(153)
Reclassification of actuarial gain/loss, in respect of employee benefit scheme to Others	2,638	3,073
	(19)	(40)
Income tax impact on above adjustments	(890)	(997)
Net profit/loss as per Ind AS	14,868	52,506
Other comprehensive income, net of income tax	(1,725)	(2,010)
Total comprehensive income for the period	13,143	50,496

8. Figures for the previous period have been regrouped/reclassified wherever necessary, to conform to the current period's classification.

Place: Gurgaon
Date : 13th February, 2017



ON BEHALF OF THE BOARD

Manoj Kumar
Manoj Kumar
Managing Director

Price Waterhouse


Chartered Accountants

The Board of Directors
GlaxoSmithKline Consumer Healthcare Limited
24-25 Floor, One Horizon Centre,
Golf Course Road,
Sector 43, DLF Phase V
Gurgaon 122002, Haryana India

1. We have reviewed the unaudited financial results of GlaxoSmithKline Consumer Healthcare Limited (the "Company") for the quarter ended December 31, 2016 which are included in the accompanying "Statement of Standalone Unaudited results for the quarter ended December 31, 2016" together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Further, the Management is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent with those used in the preparation of the Company's opening unaudited Balance Sheet as at April 1, 2015 prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matter:
 - a) Note 2 to the Statement which states that the Company has adopted Ind AS for the financial year commencing from April 1, 2016, and accordingly, the Statement has been prepared by the Company's Management in compliance with Ind AS.

Our conclusion is not qualified in respect of this matter.

For Price Waterhouse
Firm Registration Number: 301112E
Chartered Accountants


Prमित Agrawal
Partner
Membership Number: 099903

Place: Gurgaon
Date: February 13, 2017

Price Waterhouse, Building No. 8, 7th & 8th Floor, Tower B, DLF Cyber City, Gurgaon - 122 002, Haryana
T: +91 (124) 4620 000, +91 (124) 3060 000, F: +91 (124) 4620 620